IDEAYA Biosciences (NASDAQ:IDYA) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating on the stock.

Other analysts also recently issued research reports about the company. Citigroup cut their price objective on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. BTIG Research boosted their price target on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Oppenheimer decreased their price objective on shares of IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. JPMorgan Chase & Co. cut their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Buy” and a consensus price target of $56.00.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $30.69 on Tuesday. IDEAYA Biosciences has a 12 month low of $23.41 and a 12 month high of $47.74. The company has a market capitalization of $2.32 billion, a P/E ratio of -15.27 and a beta of 0.82. The company’s 50 day simple moving average is $35.08 and its 200 day simple moving average is $37.95.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). During the same quarter in the prior year, the business posted ($0.50) earnings per share. On average, analysts anticipate that IDEAYA Biosciences will post -2.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock valued at $182,355,000 after buying an additional 679,985 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in IDEAYA Biosciences by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock valued at $177,825,000 after acquiring an additional 486,222 shares in the last quarter. Janus Henderson Group PLC lifted its stake in IDEAYA Biosciences by 7.2% in the first quarter. Janus Henderson Group PLC now owns 3,808,450 shares of the company’s stock valued at $167,104,000 after acquiring an additional 256,559 shares during the last quarter. Logos Global Management LP grew its position in IDEAYA Biosciences by 13.3% in the second quarter. Logos Global Management LP now owns 1,700,000 shares of the company’s stock worth $59,687,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Fiera Capital Corp increased its stake in shares of IDEAYA Biosciences by 22.6% during the 2nd quarter. Fiera Capital Corp now owns 1,335,410 shares of the company’s stock worth $46,886,000 after purchasing an additional 246,010 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.